LON:IMM ImmuPharma (IMM) Share Price, News & Analysis GBX 1.58 -0.13 (-7.76%) As of 12:17 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About ImmuPharma Stock (LON:IMM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ImmuPharma alerts:Sign Up Key Stats Today's Range 1.58▼ 1.8050-Day Range 1.69▼ 2.7552-Week Range 0.85▼ 7.40Volume2.54 million shsAverage Volume6.26 million shsMarket Capitalization£6.72 millionP/E RatioN/ADividend Yield0.77%Price TargetN/AConsensus RatingN/A Company Overview ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. Read More Receive IMM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address IMM Stock News HeadlinesImmupharma Share Chat. Chat About IMM Shares - Stock Quote, Charts ...August 5 at 8:52 PM | lse.co.ukImmuPharma celebrates "significant milestone" for P140 platformMarch 14, 2025 | lse.co.ukAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.August 8 at 2:00 AM | Brownstone Research (Ad)ImmuPharma addresses recent share price volatilityJanuary 28, 2025 | msn.comWe Think ImmuPharma (LON:IMM) Needs To Drive Business Growth CarefullyJanuary 25, 2025 | finance.yahoo.comImmuPharma PLC (25I.MU)January 18, 2025 | ca.finance.yahoo.comSMALL CAP MOVERS: ImmuPharma lifted by groundbreaking researchJanuary 10, 2025 | msn.comAIM WINNERS & LOSERS: ImmuPharma jumps; Impax Asset hit by outflowsJanuary 9, 2025 | lse.co.ukSee More Headlines IMM Stock Analysis - Frequently Asked Questions How have IMM shares performed this year? ImmuPharma's stock was trading at GBX 1.18 on January 1st, 2025. Since then, IMM stock has increased by 34.1% and is now trading at GBX 1.58. How were ImmuPharma's earnings last quarter? ImmuPharma plc (LON:IMM) announced its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.38) earnings per share for the quarter. ImmuPharma had a negative trailing twelve-month return on equity of 131.41% and a net margin of 3,519.56%. How do I buy shares of ImmuPharma? Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of ImmuPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuPharma investors own include Castleton Technology (CTP), 4D pharma (DDDD), Motif Bio (MTFB), Thor Energy (THR), Aminex (AEX) and GSK (GSK). Company Calendar Last Earnings8/06/2025Today8/08/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:IMM CIKN/A Webwww.immupharma.org Phone+44-20-71524080FaxN/AEmployees13Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£2.51 million Net Margins3,519.56% Pretax MarginN/A Return on Equity-131.41% Return on Assets-43.00% Debt Debt-to-Equity RatioN/A Current Ratio1.60 Quick Ratio1.03 Sales & Book Value Annual Sales-£71.31 thousand Price / Sales-95.32 Cash FlowGBX 0.08 per share Price / Cash Flow20.50 Book ValueGBX 0.65 per share Price / Book2.48Miscellaneous Outstanding Shares425,094,500Free FloatN/AMarket Cap£6.80 million OptionableNot Optionable Beta1.53 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (LON:IMM) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 While the market chops sideways and headlines dominate the news cycle, a small group of traders is quietly tak...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.